I am a medical epidemiologist (MD in 1988 at Paris V, specialisation in rheumatology in 1990, Paris V, and DrPH from Harvard School of Public Health in 1993) specialized in infectious diseases epidemiology. After working at WHO at the clinical research unit of the Global Program on AIDS (1993-1994), I spent five years in Ethiopia and two years in the Netherlands working as the Program Manager of the Ethio-Netherlands AIDS Research Project (1994-2001). In 2002, I joined Institut Pasteur to launch the Emerging Diseases Epidemiology unit. There, my focus has been on viral hepatitis C (North-Coordinator of the ANRS research site on viral hepatitis; www.hepnile.org) and emerging infections such as the SARS (Scientific Coordinator of the EPISARS project which aimed prevent the re-emergence of SARS through the control of its animal reservoir) and the MERS-CoV. I also have a strong teaching involvement, as co-Director and founder of the Pasteur-Cnam School of Public Health (http://ecole-pasteur.cnam.fr), and coordinator of a master in public health with strong focus on infectious diseases. In 2014, I was appointed as Director of the newly created Pasteur Centre for Global Health Research and Education.
INCEPTION – Institut Convergence for the study of Emergence of Pathology Through Individuals and Populations
Inception Goal The Inception’s goal is to develop a core structure to mobilize data resources, numerical sciences, and fundamental experimental biology in a range of health issues. Inception program uses Integrative Biology, Social Science […]
Emergency response to global threats of emerging and re-emerging pathogens
With over 125 years’ experience with infectious diseases, the Institut Pasteur and the Institut Pasteur International Network (IPIN), which is composed of 33 research institutes in 26 countries and five continents, are ideally positioned […]
Protected: Pasteur Human Genome
There is no excerpt because this is a protected post.
ANRS 12332 HepNile: Evaluation of “Real Life” Efficacy and Safety of antiviral treatments including new Direct Antiviral Agents among patients treated for Chronic Hepatitis C at Egyptian National Treatment Centres
Background: Clinical trials are performed under optimal conditions where patients are highly selected without co-morbidities, clinical supervision is provided by specialists, and strict protocols are used to enhance patient compliance. Due to this, results […]
HCV research in Egypt
Funding: ANRS & EC. The main research objectives of this multidisciplinary network funded by the ANRS and the EC are the assessment of the burden of HCV infection and disease in Egypt, the study […]
Epidemiology of Buruli ulcer in Cameroon
Funding: ANR, Fondation Raoul Follereau, Fondation SANOFI Espoir. In this new research program, we will conduct for the first time the simultaneous collection of environmental (plants and insects) and human samples in two […]
Acute Bacterial Meningitis Project: Investigation of the spatio-temporal dynamics of meningitis epidemics in Niger and the associated ecologic risk factors
Funding : DCI Monaco. In collaboration with epidemiologists from the Centre de Recherche Médicale et Sanitaire (CERMES) in Niamey, we are using recent advances in Geographic Information Systems and statistical methodology to investigate […]
2018Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus, Gut 2018 Apr;.
2017Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis, J. Viral Hepat. 2017 Dec;.
2017An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms, PLoS ONE 2017;12(9):e0183084.
2017study of the humoral immune response towards HCV genotype 4 using a bead-based multiplex serological assay, High-Trhoughput 2017, 6,15.
2016Diagnostic accuracy of the γ-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4, Gut 2016 Jul;.
2016Association between Guillain-Barré syndrome and Zika virus infection – Authors’ reply, Lancet 2016 Jun;387(10038):2600.
2016The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment, Liver Int. 2016 Jun;.
2016Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study, Lancet 2016 May;387(10033):2125-32.
2016Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study, Lancet 2016 Apr;387(10027):1531-9.
2016Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt, J. Hepatol. 2016 Jun;64(6):1240-6.
+View full list of publications